Leerink Partnrs Has Strong Estimate for Bruker Q2 Earnings

Bruker Corporation (NASDAQ:BRKR - Free Report) - Equities research analysts at Leerink Partnrs upped their Q2 2025 earnings per share estimates for Bruker in a report issued on Thursday, July 17th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will earn $0.38 per share for the quarter, up from their prior estimate of $0.37. The consensus estimate for Bruker's current full-year earnings is $2.69 per share. Leerink Partnrs also issued estimates for Bruker's Q3 2025 earnings at $0.64 EPS, Q4 2025 earnings at $0.93 EPS, Q3 2026 earnings at $0.68 EPS and Q4 2026 earnings at $0.99 EPS.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The medical research company reported $0.47 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.46 by $0.01. Bruker had a return on equity of 19.47% and a net margin of 2.31%. The firm had revenue of $801.40 million for the quarter, compared to analysts' expectations of $763.83 million. During the same quarter last year, the business earned $0.53 earnings per share. The company's revenue was up 11.0% compared to the same quarter last year.

Other equities research analysts also recently issued research reports about the stock. Stifel Nicolaus lowered their target price on shares of Bruker from $57.00 to $48.00 and set a "hold" rating for the company in a research note on Thursday, May 8th. Wells Fargo & Company lowered their target price on shares of Bruker from $75.00 to $60.00 and set an "overweight" rating for the company in a research note on Thursday, April 17th. Barclays lowered their target price on shares of Bruker from $50.00 to $46.00 and set an "overweight" rating for the company in a research note on Thursday, May 8th. Bank of America lowered their target price on shares of Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Finally, Citigroup downgraded shares of Bruker from a "strong-buy" rating to a "hold" rating and lowered their target price for the company from $50.00 to $40.00 in a research note on Thursday, May 22nd. Six research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $52.89.

Bruker Stock Down 3.9%

Shares of NASDAQ:BRKR opened at $40.55 on Monday. Bruker has a 52 week low of $34.10 and a 52 week high of $72.94. The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.74 and a current ratio of 1.57. The company has a market capitalization of $6.14 billion, a PE ratio of 77.98, a PEG ratio of 2.73 and a beta of 1.18. The company has a 50 day moving average price of $39.43 and a two-hundred day moving average price of $44.79.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Quadrant Capital Group LLC boosted its holdings in Bruker by 18.2% during the fourth quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock worth $75,000 after purchasing an additional 196 shares during the last quarter. Insigneo Advisory Services LLC boosted its holdings in Bruker by 4.7% during the fourth quarter. Insigneo Advisory Services LLC now owns 4,880 shares of the medical research company's stock worth $286,000 after purchasing an additional 218 shares during the last quarter. CGN Advisors LLC boosted its holdings in Bruker by 1.4% during the first quarter. CGN Advisors LLC now owns 22,014 shares of the medical research company's stock worth $919,000 after purchasing an additional 296 shares during the last quarter. New York State Teachers Retirement System boosted its holdings in Bruker by 0.8% during the first quarter. New York State Teachers Retirement System now owns 37,115 shares of the medical research company's stock worth $1,549,000 after purchasing an additional 300 shares during the last quarter. Finally, State of Michigan Retirement System boosted its holdings in Bruker by 1.1% during the first quarter. State of Michigan Retirement System now owns 26,493 shares of the medical research company's stock worth $1,106,000 after purchasing an additional 300 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company's stock.

Insider Buying and Selling at Bruker

In related news, CEO Frank H. Laukien purchased 2,608 shares of Bruker stock in a transaction dated Friday, June 6th. The stock was bought at an average price of $38.36 per share, for a total transaction of $100,042.88. Following the completion of the acquisition, the chief executive officer directly owned 38,462,171 shares of the company's stock, valued at $1,475,408,879.56. This represents a 0.01% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 27.30% of the stock is owned by company insiders.

Bruker Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Monday, June 16th were issued a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.49%. The ex-dividend date was Monday, June 16th. Bruker's dividend payout ratio (DPR) is presently 38.46%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.